IDEXX Laboratories Inc. (NASDAQ: IDXX) stock closed at 360.2 per share at the end of the most recent trading day (a -0.55% change compared to the prior day closing price) with a volume of 531.23K shares and market capitalization of 30.26B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 9300 people. IDEXX Laboratories Inc. CEO is Jonathan J. Mazelsky.

The one-year performance of IDEXX Laboratories Inc. stock is -31.67%, while year-to-date (YTD) performance is -45.3%. IDXX stock has a five-year performance of 123.67%. Its 52-week range is between 330.66 and 706.95, which gives IDXX stock a 52-week price range ratio of 7.85%

IDEXX Laboratories Inc. currently has a PE ratio of 42.50, a price-to-book (PB) ratio of 47.56, a price-to-sale (PS) ratio of 9.24, a price to cashflow ratio of 41.90, a PEG ratio of 2.32, a ROA of 30.67%, a ROC of 41.80% and a ROE of 112.72%. The company’s profit margin is 22.44%, its EBITDA margin is 31.70%, and its revenue ttm is $3.27 Billion , which makes it $38.98 revenue per share.

Of the last four earnings reports from IDEXX Laboratories Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.25 for the next earnings report. IDEXX Laboratories Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for IDEXX Laboratories Inc. is Moderate Buy (1.81), with a target price of $612.17, which is +69.95% compared to the current price. The earnings rating for IDEXX Laboratories Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

IDEXX Laboratories Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

IDEXX Laboratories Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.64, ATR14 : 20.15, CCI20 : -77.57, Chaikin Money Flow : -0.11, MACD : -42.55, Money Flow Index : 17.90, ROC : -19.66, RSI : 28.99, STOCH (14,3) : 22.60, STOCH RSI : 0.97, UO : 39.81, Williams %R : -77.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of IDEXX Laboratories Inc. in the last 12-months were: Brian P. Mckeon (Option Excercise at a value of $3 189 519), Brian P. Mckeon (Sold 45 535 shares of value $28 485 272 ), Bruce L. Claflin (Option Excercise at a value of $307 898), Daniel M. Junius (Option Excercise at a value of $416 670), Daniel M. Junius (Sold 4 902 shares of value $2 981 273 ), Giovani Twigge (Option Excercise at a value of $7 556 014), Giovani Twigge (Sold 40 590 shares of value $28 341 797 ), James F. Polewaczyk (Option Excercise at a value of $678 500), James F. Polewaczyk (Sold 14 595 shares of value $8 527 691 ), Jonathan J. Mazelsky (Option Excercise at a value of $0), Jonathan J. Mazelsky (Sold 6 000 shares of value $4 051 262 ), Jonathan W. Ayers (Option Excercise at a value of $2 652 567), Jonathan W. Ayers (Sold 32 342 shares of value $17 657 279 ), Kathy V. Turner (Option Excercise at a value of $793 175), Kathy V. Turner (Sold 18 852 shares of value $11 033 724 ), M. Anne Szostak (Sold 2 400 shares of value $1 649 540 ), Michael J. Lane (Option Excercise at a value of $802 037), Michael J. Lane (Sold 6 494 shares of value $4 491 536 ), Nimrata Hunt (Option Excercise at a value of $174 085), Nimrata Hunt (Sold 538 shares of value $378 214 ), Sharon E. Underberg (Option Excercise at a value of $99 952)